We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
CUPRIOR (JACE Pharma Pty Ltd)
Product name
CUPRIOR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
212 (255 working days)
Active ingredients
trientine tetrahydrochloride
Registration type
NCE/NBE
Indication
CUPRIOR (film-coated tablet) is indicated for the treatment of Wilson's disease in adults, adolescents and children≥5 years intolerant to D-penicillamine therapy.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.